Spring Health
-35%
est. 2Y upside i
Mental health benefits platform for employers and health plans
Rank
#2915
Sector
Healthtech
Est. Liquidity
~2Y
Data Quality
Data: MediumThe expected equity upside over 2 years is -35%, driven by a high entry multiple of 5.28x and competitive pressure.
Last updated: July 19, 2026
IPO window opens within 24 months (management signals 18-24 months). Exit multiple holds at 5x, driven by category leadership and strong revenue growth to $1.02B. Expected return after 20% dilution: 33.9%.
Multiple converges to 3x (high end of comp range) as growth decelerates. Revenue reaches $1.02B, but entry multiple of 5.28x compresses. After 20% dilution, expected return: -27.7%.
Multiple compresses to 2x due to incumbent pressure and regulatory fines. Revenue growth disappoints. After 20% dilution, common stock loses 58.5%. Preference stack of $474M not triggered.
Preference Stack Risk
moderateFunding Intensity
1440%Total preferred stock of $474M (1x non-participating) sits behind common, representing 14.4% of entry valuation.
Dilution Risk
moderatePotential future raise before IPO could dilute existing shareholders by ~20%.
Secondary Liquidity
noneNo secondary market transactions reported; liquidity likely only via IPO.
Questions to Ask at the Interview
Strategic questions based on Spring Health's data — designed to show you've done your homework.
- 1
“How does Spring Health plan to differentiate from incumbents like Lyra Health and maintain its growth rate?”
- 2
“What is the company's path to profitability, considering the recent regulatory fine and acquisition of Alma?”
- 3
“Given the pre-IPO status, what is the typical equity distribution timeline for employees, and how does the company think about secondary liquidity?”
Community
Valuation Sentiment
Our model estimates -35% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.